Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;30(4):1059-1066.
doi: 10.1111/hae.15070. Epub 2024 Jun 25.

Minimal interference of concizumab with standard clinical coagulation laboratory assays - An in vitro study

Cecilia Augustsson  1 , Karin Strandberg  1 , Marianne Kjalke  2
Affiliations

Minimal interference of concizumab with standard clinical coagulation laboratory assays - An in vitro study

Cecilia Augustsson et al. Haemophilia. 2024 Jul.

Abstract

Introduction: Non-factor replacement therapies are emerging as prophylactic treatment options in haemophilia A or B (HA/HB) with and without inhibitors. Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody preventing factor (F)Xa inhibition and enhancing thrombin generation. Based on experience with other non-factor therapies and extended half-life products, there is a focus on potential interference with common clinical coagulation assays used to monitor patients treated with concizumab.

Aim: To evaluate the impact of concizumab on standard clinical coagulation assays.

Methods: Plasma samples (normal, HA/HB with/without inhibitors) in the presence/absence of added concizumab (250-16,000 ng/mL) were analysed in clinical assays including activated partial thromboplastin time (aPTT), prothrombin time (PT), FVIII and FIX one-stage clot and chromogenic substrate assay, assays for detecting FVIII or FIX inhibitors and other assays for coagulation factors.

Results: Concizumab did not impact PT assays, but resulted in a small shortening of aPTT (up to 5 s in haemophilia plasma and 0.4 s in normal plasma). Concizumab had no, or only a minor impact on FVIII and FIX activity assays or Bethesda inhibitor assays. FXI and FXII activity in normal plasma, as measured by single factor aPTT-based assay, was significantly increased in the presence of concizumab (+11% each). This was also the case for FVII and FX measured by PT-based assays using plasma with 25% of FVII or FX (+64% and +22%, respectively).

Conclusion: The presence of concizumab did not, or only slightly, influence the outcome of standard clinical coagulation assays relevant for HA and HB.

Keywords: blood coagulation tests; coagulation disorders; concizumab; haemophilia; prophylaxis.

PubMed Disclaimer

References

REFERENCES

    1. Müller J, Miesbach W, Prüller F, Siegemund T, Scholz U, Sachs UJ. An update on laboratory diagnostics in haemophilia A and B. Hamostaseologie. 2022;42(4):248‐260. doi:10.1055/a‐1665‐6232
    1. Adamkewicz JI, Chen DC, Paz‐Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119(7):1084‐1093. doi:10.1055/s‐0039‐1688687
    1. Monroe DM, Hoffman M. What does it take to make the perfect clot. Arterioscler Thromb Vasc Biol. 2006;26(1):41‐48. doi:10.1161/01.Atv.0000193624.28251.83
    1. Adcock DM, Strandberg K, Shima M, Marlar RA. Advantages, disadvantages and optimization of one‐stage and chromogenic factor activity assays in haemophilia A and B. Int J Lab Hematol. 2018;40(6):621‐629. doi:10.1111/ijlh.12877
    1. Marlar RA, Strandberg K, Shima M, Adcock DM. Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B. Eur J Haematol. 2020;104(1):3‐14. doi:10.1111/ejh.13339

MeSH terms

Substances

Grants and funding

LinkOut - more resources